RxDoctor Payments DataLook up a doctor →

Jason Milligan, MD

Family Medicine · Bossier City, LANPI 1114138864

Payments from drug & device makers

$15,473in general payments, 2019–2025

Across 1,036 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Lilly USA, LLC$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Amgen$997
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$15,401100%
  • Education$720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,473 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$60,947
Medicare patients
126
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$49,271
MounjaroTirzepatide44$49,070
JanuviaSitagliptin Phosphate11$12,387
VascepaIcosapent Ethyl16$8,801
Rosuvastatin Calcium80$1,048
Atorvastatin Calcium94$869
Pantoprazole Sodium55$822
Tamsulosin Hcl53$742
Pravastatin Sodium41$729
Duloxetine Hcl35$726
Olmesartan Medoxomil55$679
Nifedipine ErNifedipine24$573
Amlodipine Besylate112$572
Losartan Potassium66$547
Omeprazole59$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,414$49,27135 claims
Lilly USA, LLCMounjaro$1,689$49,07044 claims
MerckJanuvia$636$12,38711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →